CX-4945 – 500 µg

Brand:
Cayman
CAS:
1009820-21-6
Storage:
-20
UN-No:
Non-Hazardous - /

CX-4945 is a potent, orally bioavailable inhibitor of casein kinase 2 (CK2; Ki = 0.38 nM) that competes with ATP by filling the small ATP binding site on the catalytic CK2α subunit, conferring selectivity.{27517,27516,27518} It inhibits proliferation in a panel of cancer cell lines that overexpress CK2 and prevents tumor growth of breast and pancreatic cancer cell xenografts in mice.{27518} CX-4945 blocks survival and induces apoptosis in cancer stem cells and is effective against glioblastomas and acute myeloid leukemia cells.{27520,27519} CX-4945 also inhibits Cdc2-like kinases (Clk; IC50s = 82.3, 3.8, and 90 nM for Clk1, Clk2, and Clk3, respectively), interfering with alternative splicing.{26173}  

 

Out of stock

SKU: - Category:

Description

A potent, orally bioavailable inhibitor of casein kinase 2 (CK2; Ki = 0.38 nM); inhibits proliferation in a panel of cancer cell lines that overexpress CK2 and prevents tumor growth of breast and pancreatic cancer cell xenografts in mice


Formal name: 5-[(3-chlorophenyl)amino]-benzo[c]-2,6-naphthyridine-8-carboxylic acid

Synonyms:  Silmitasertib

Molecular weight: 349.8

CAS: 1009820-21-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|CK2||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|Casein Kinase Signaling